Table 1.
Clinical characteristics of patients with GC according to the RTL in the training, validation and combining sets.
| Characteristics | Training set (n = 112) | Validation set (n = 581) | Combining set (n = 693) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Short RTL (n = 57) | Long RTL (n = 55) | P value | Short RTL (n = 326) | Long RTL (n = 255) | P value | Short RTL (n = 383) | Long RTL (n = 310) | P value | |
| Age, years | 61.67 (11.39) | 59.91 (10.32) | 0.277b | 58.15 (9.93) | 56.96 (11.04) | 0.101b | 58.57 (10.21) | 57.36 (10.93) | 0.203b |
| Sex | |||||||||
| Male | 48 (84.2) | 43 (78.2) | 257 (78.8) | 190 (74.5) | 305 (79.6) | 233 (75.2) | |||
| Female | 9 (15.8) | 12 (21.8) | 0.414a | 69 (21.2) | 65 (25.5) | 0.219a | 78 (20.4) | 77 (24.8) | 0.160a |
| Tumor site | |||||||||
| Proximal | 9 (15.8) | 14 (25.5) | 74 (22.7) | 73 (28.6) | 83 (21.6) | 87 (28.1) | |||
| Middle | 22 (35.6) | 26 (47.3) | 128 (39.3) | 103 (40.4) | 150 (39.2) | 129 (41.6) | |||
| Distal | 26 (48.6) | 15 (27.2) | 0.114a | 124 (38.0) | 79 (31.0) | 0.131a | 150 (39.2) | 94 (30.3) | 0.082a |
| TNM stage | |||||||||
| I | 14 (24.5) | 8 (14.5) | 74 (22.7) | 52 (20.4) | 88 (23.1) | 60 (19.7) | |||
| II | 21 (36.8) | 25 (45.5) | 155 (47.5) | 105 (41.2) | 176 (44.7) | 130 (43.6) | |||
| III | 20 (35.1) | 20 (36.4) | 74 (22.7) | 74 (29.0) | 94 (25.6) | 94 (28.6) | |||
| IV | 2 (3.6) | 2 (3.6) | 0.766a | 23 (7.1) | 24 (9.4) | 0.217a | 25 (6.6) | 26 (8.1) | 0.563a |
| Differentiation | |||||||||
| Well | 9 (15.8) | 10 (18.2) | 50 (15.3) | 30 (11.8) | 59 (15.4) | 40 (12.9) | |||
| Moderate | 23 (40.4) | 15 (27.3) | 129 (39.6) | 94 (36.9) | 152 (39.7) | 109 (35.2) | |||
| Poor | 25 (43.8) | 30 (54.5) | 0.340a | 147 (45.1) | 131 (51.3) | 0.249a | 172 (44.9) | 161 (51.9) | 0.179a |
| Lauren classificationd | |||||||||
| Intestinal | 23 (41.8) | 25 (47.2) | 135 (41.7) | 110 (43.7) | 158 (41.7) | 135 (44.3) | |||
| Diffuse | 32 (58.2) | 28 (52.8) | 0.471a | 189 (58.3) | 142 (56.3) | 0.593a | 221 (58.3) | 170 (55.7) | 0.487a |
| Chemotherapy | |||||||||
| No | 21 (28.1) | 23 (32.7) | 144 (41.2) | 95 (37.3) | 165 (33.1) | 118 (38.1) | |||
| Yes | 36 (71.9) | 32 (67.3) | 0.590a | 182 (58.8) | 160 (62.7) | 0.103a | 218 (56.9) | 192 (61.9) | 0.182a |
| Relapse | |||||||||
| Yes | 54 (94.7) | 35 (63.6) | 167 (51.2) | 107 (42.0) | 221 (57.7) | 142 (45.8) | |||
| No | 3 (5.3) | 20 (36.4) | <0.001c | 159 (48.8) | 148 (58.0) | 0.001c | 162 (42.3) | 168 (54.2) | <0.001c |
| Death | |||||||||
| Yes | 48 (84.2) | 28 (50.9) | 131 (40.2) | 73 (28.6) | 179 (46.7) | 101 (32.6) | |||
| No | 9 (15.8) | 27 (49.1) | <0.001c | 195 (59.8) | 182 (71.4) | 0.003c | 204 (53.3) | 209 (67.4) | <0.001c |
Notes: Data are mean (SD) or n (%), unless otherwise stated. TNM, tumor‐node‐metastasis; RTL, relative telomere length.
a
The P values were calculated using a Pearson Chi‐Square test.
b
The P values were calculated using an unpaired student's t test.
c
The P values were calculated using Log‐rank test.
d
Other classification were censored due to the small number of subjects in this subgroup.